All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Psoriasis is a common auto-immune disease affecting the skin and joints. Current literature regarding psoriasis in the context of pregnancy is limited and contradictory.1 The Psoriasis Hub previously reported on key findings from a nationwide Danish case-control study investigating the association between psoriasis and adverse pregnancy outcomes in around half a million women.
In order to further evaluate the association between psoriasis in pregnancy and maternal and neonatal outcomes, Krim et al.1 conducted a population-based study within a cohort of 13 million births. Below, we summarize the key findings.
A population based, retrospective cohort study was conducted using the 1999–2015 United States (U.S.) Healthcare Cost and Utilization Project Nationwide Inpatient Sample, as outlined in Figure 1.
Figure 1. Study design*
CI, confidence interval; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.
*Adapted from Krim, et al.1
Initial analysis determined the annual prevalence of psoriasis in pregnancy between 1999 and 2015 and summarized baseline characteristics of psoriasis and non-psoriasis groups. Variables and outcomes of interest included maternal age, race, obesity, smoker status, comorbidities, income, insurance status, and hospital type.
Notable differentiated risk outcomes, summarized in Table 1, were as follows:
Table 1. Notable differentiated risk outcomes*
Risk outcome, % |
No psoriasis |
Psoriasis |
OR |
95% CI |
p value |
---|---|---|---|---|---|
Antepartum |
|||||
Gestational diabetes |
5.75 |
8.75 |
1.27 |
1.13–1.42 |
<0.0001 |
Preeclampsia |
3.9 |
6.5 |
1.4 |
1.2–1.6 |
<0.0001 |
Intrapartum and postpartum |
|||||
Chorioamnionitis |
1.8 |
2.3 |
1.3 |
1.0–1.6 |
<0.05 |
Cesarean section |
30.2 |
39.0 |
1.2 |
1.1–1.3 |
<0.0001 |
Anemia |
0.54 |
0.70 |
1.74 |
1.18–2.57 |
0.01 |
Receiving blood |
0.8 |
1.2 |
1.4 |
1.0–1.8 |
<0.05 |
Myocardial infarction |
<0.1 |
0.1 |
13.4 |
3.3–54.6 |
<0.001 |
Neonatal |
|||||
Preterm birth |
7.1 |
8.9 |
1.2 |
1.1–1.4 |
<0.01 |
Congenital |
0.4 |
1.0 |
1.7 |
1.2–2.4 |
<0.01 |
Intrauterine growth |
2.0 |
3.4 |
1.5 |
1.2–1.7 |
<0.0001 |
CI, confidence interval; OR, odds ratio. |
These results indicate that women with psoriasis and their newborns are more likely to experience adverse outcomes of pregnancy than the general population. The findings suggest that women with psoriasis would benefit from close monitoring by their obstetrician and dermatologist during pregnancy. Krim et al. conclude that further investigation into psoriasis management during pregnancy is warranted.
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox